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Abstract 
Objective: To investigate the utility of serum pyridoxal 5′-phosphate (PLP), pyridoxal (PL) 
and, 4-pyridoxic acid (PA) as a diagnostic marker of hypophosphatasia (HPP) and an indicator 
of the effect of, and patient compliance with, enzyme replacement therapy (ERT), we 
measured PLP, PL, and PA concentrations in serum samples from HPP patients with and 
without ERT. 
Methods: Blood samples were collected from HPP patients and serum was frozen as soon as 
possible (mostly within one hour). PLP, PL, and PA concentrations were analyzed using 
high-performance liquid chromatography with fluorescence detection after pre-column 
derivatization by semicarbazide. We investigated which metabolites are associated with 
clinical phenotypes and how these metabolites change with ERT. 
Results: Serum samples from 20 HPP patients were analyzed. The PLP-to-PL ratio and PLP 
concentration were elevated in all HPP patients. They correlated negatively with serum 
alkaline phosphatase (ALP) activity and showed higher values in more severe phenotypes 
(perinatal severe and infantile HPP) compared with other phenotypes. PL concentration was 
reduced only in perinatal severe HPP. ERT reduced the PLP-to-PL ratio to mildly reduced or 
low-normal levels and the PLP concentration was reduced to normal or mildly elevated levels. 
Urine phosphoethanolamine (PEA) concentration did not return to normal levels with ERT in 
most patients. 
Conclusions: The serum PLP-to-PL ratio is a better indicator of the effect of ERT for HPP 
than serum PLP and urine PEA concentrations, and a PLP-to-PL ratio of <4.0 is a good 
indicator of the effect of, and patient compliance with, ERT. 
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1. Introduction 
Hypophosphatasia (HPP; MIM #241500, #241510, and #146300) is an inborn error of 
metabolism that is characterized mainly by defective mineralization of bone and/or teeth and 
low serum alkaline phosphatase (ALP) activity [1]. HPP is caused by abnormalities in the 
ALPL gene that encodes tissue-nonspecific ALP (TNSALP; EC 3.1.3.1). The onset age varies 
among patients, ranging from the prenatal period to adulthood. Based on the onset age and 
severity, six clinical forms are recognized: perinatal severe, perinatal benign, infantile, 
childhood, adult, and odonto-HPP. 
 
In HPP, three metabolites are known to be elevated: urine phosphoethanolamine (PEA), 
plasma/serum pyridoxal 5′-phosphate (PLP), and inorganic pyrophosphate (PPi) [1]. TNSALP, 
which has reduced or absent activity in HPP, uses these metabolites as its substrate. Elevated 
PPi inhibits deposition of hydroxyapatite in bone, causing defective skeletal mineralization 
[2]. Alteration of vitamin B6 (VB6) metabolism reflected by abnormal PLP (active form of 
VB6) is thought to be associated with epileptic seizures [3]. 
 
In recent years, recombinant TNSALP enzyme replacement therapy (ERT) has become 
available by approval of asfotase alfa, which contains the catalytic TNSALP domain, the 
human immunoglobulin G1 Fc region, and L-aspartate residues [4]. This therapy improved 
skeletal radiographic findings and pulmonary and physical function in young patients with 
life-threatening HPP [4, 5]. 
 
Monitoring the effect of, and patient compliance with, ERT is important in clinical practice 
for optimization of treatment. A monitoring guidance was recently published and the role of 
assays for PLP, PEA, and PPi was described [6]. However, the target concentrations of these 
Akiyama et al., page 5 
metabolites were not clearly mentioned and there was no description about other PLP-related 
metabolites, such as pyridoxal (PL). Because PLP is a substrate and PL is a product of the 
enzymatic reaction of ALP, the simultaneous assay of PLP and PL may provide a better 
understanding of in vivo ALP activity in the blood during ERT than the PLP assay alone. 
Additionally, 4-pyridoxic acid (PA, a metabolite of PL) is a good biomarker for the VB6 
status as well as PLP and PL [7]. 
 
In this study, we aimed to determine PLP, PL, and PA concentrations in serum samples 
obtained from HPP patients with and without ERT. We investigated which metabolites are 
associated with clinical phenotypes and how these metabolites are changed by ERT. We 
hypothesized that the PLP-to-PL ratio is a better indicator of the effect of, and patient 
compliance with, ERT than serum PLP and urine PEA concentrations. 
 
2. Material and methods 
2.1. Subjects 
Subjects consisted of HPP patients who underwent blood and urine tests to diagnose HPP or 
to check adverse effects during ERT with asfotase alfa. A diagnosis of HPP was made based 
on the following: 1) low serum ALP activity compared with age- and sex-matched reference 
values; and either 2) clinical symptoms suggestive of HPP (skeletal symptoms such as 
defective mineralization, deformities, rickets, and/or premature loss of primary teeth); or 3) 
confirmation of ALPL gene abnormality, or both. Blood samples obtained during VB6 therapy 
were excluded. We also collected clinical data including phenotype, use of asfotase alfa, 
epileptic seizures, disability in daily activities measured using a modified Rankin Scale, 
serum ALP activity, urine PEA concentration, and ALPL gene abnormalities. This study was 
performed in accordance with the Declaration of Helsinki and approved by the Research 
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Ethics Board at Okayama University Hospital. Written informed consent was obtained from 
the patients’ parents or guardians. 
 
2.2. Collection of serum samples 
Blood samples were protected from light and serum was separated by centrifugation and 
frozen at either −20°C or −80°C. We recommended that the samples should be frozen within 1 
hour after blood collection, particularly for serum samples with ERT. When this protocol 
could not be followed, the time between blood collection and protection from light, and the 
time between blood collection and storage in a freezer were documented. The frozen samples 
were shipped on dry ice to our laboratory at Okayama University Hospital and kept frozen at 
−80°C until analysis. 
 
2.3. Assay of PLP, PL and PA 
The frozen serum samples were thawed in a refrigerator at 4°C. Assay of PLP, PL and PA 
concentrations was conducted using high-performance liquid chromatography after 
derivatization of PLP and PL by semicarbazide hydrochloride under mildly acidic conditions, 
as previously reported [8, 9]. The PLP-to-PL ratio (PLP/PL), which is considered to reflect 
the activity of ALP (conversion of PLP to PL) and pyridoxal kinase (conversion of PL to PLP), 
was calculated. 
 
2.4. Stability of PLP and PL in the serum samples with ERT 
Keeping serum samples with ERT for a long time at room temperature may significantly 
affect the assay results of PLP and PL [6]. Because no test tubes containing an ALP inhibitor 
are commercially available in Japan, we investigated the influence of asfotase alfa on PLP and 
PL concentrations in serum samples collected using regular serum collection tubes. Serum 
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samples with ERT were divided into four aliquots and pre-treated under four different 
conditions: 1) serum was diluted two-fold with levamisole (20 mmol/L), an ALP inhibitor, in 
ultrapure water, and immediately derivatized by semicarbazide hydrochloride; 2) serum was 
diluted two-fold with ultrapure water (no levamisole) and immediately derivatized; 3) serum 
was diluted the same as in 2), kept at 4°C in the dark for 1 hour, then derivatized; and 4) 
serum was diluted the same as in 2), kept at the room temperature (24°C, air-conditioned) for 
1 hour, then derivatized. PLP and PL were determined and their concentrations were 
compared among these four conditions. 
 
2.5. Statistical analysis 
To increase reliability of statistical analysis, we excluded the following serum samples: 1) 
samples without ERT protected from light more than 1 hour or frozen more than 6 hours after 
blood collection; 2) samples with ERT frozen more than 1 hour after blood collection; 3) 
samples with no documentation about the timing of protection from light and freezing; and 4) 
samples under the possible influence of a mother’s VB6 supplementation (described in the 
Results). Spearman’s correlation analysis and multiple regression analysis were performed 
using R 3.4.2 (https://cran.r-project.org/). The significance level was set to 0.05. 
 
3. Results 
3.1. Subject characteristics 
There were 20 patients with HPP (13 females) enrolled into this study. Their clinical 
characteristics are presented in Table 1. Case 4 was reported elsewhere [10]. Eight patients 
had serum samples collected during ERT, and 18 patients had serum samples collected 
without ERT. There was one patient (Case 17) who temporarily discontinued ERT because of 
a possible allergic reaction. There was a 19-year-old patient (Case 16) with no skeletal or 
Akiyama et al., page 8 
dental symptoms but who had an epileptic seizure, for which VB6 was not administered. 
Because this patient had low serum ALP activity and an ALPL gene abnormality, we included 
this patient as an adult HPP patient. 
 
Epileptic seizures were observed in five patients (Cases 1, 4, 6, 11, and 16). There were two 
patients (Cases 1 and 4) with VB6-responsive seizures, one patient (Case 11) with VB6 
non-responsive seizures, and two patients (Cases 6 and 16) who had seizures but VB6 was not 
administered. 
 
Modified Rankin Scale scores were high (severe disability in daily activities) in perinatal 
severe HPP but low with other phenotypes, except one patient (Case 11) who had a 
complication of cerebral palsy and VB6 non-responsive epilepsy. Patients with perinatal 
severe HPP who continued ERT for more than 6 months (Cases 2, 3, and 4) had stable or 
improved disability in daily activities. 
 
Serum ALP activities were low in all patients and urine PEA concentrations were elevated 
except for one patient (Case 5) without ERT. Two patients (Cases 1 and 4) with 
VB6-responsive seizures showed the lowest serum ALP activities (14 and 11 U/L). After ERT 
started, there was a dramatic increase in serum ALP activity but PEA concentration decreased 
to within the normal range in only one patient (Case 3). The most common ALPL gene 
abnormality in our patients was c.1559delT, p.L520fs, which is characteristic in Japanese HPP 
patients [11]. 
 
3.2. Stability of PLP and PL with ERT 
The assay results of serum samples (n = 4) collected during ERT with different pre-treatment 
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conditions are shown in Figure 1. After thawing at 4°C in a refrigerator, samples with no 
added levamisole derivatized immediately or after 60 minutes at 4°C showed no or a slight 
change in the PLP concentration (−5.0 to +5.9%) and no or a slight increase in the PL 
concentration (±0.0 to +4.9%) compared with serum samples with levamisole. Samples 
without levamisole derivatized after 60 minutes at 24°C showed no or a mild decrease in the 
PLP concentration (−5.7 to ±0.0%) and a mild increase in the PL concentration (+1.9 to 
+7.7%). Addition of levamisole impaired chromatographic separation of the PA peak. 
Therefore, we chose to derivatize serum samples after thawing at 4°C without levamisole for 
subsequent analyses. 
 
3.3. PLP, PL, and PA concentrations without ERT 
The results in samples without ERT are shown by closed symbols in Figure 2. There was a 
sample protected from light more than 1 hour after blood collection (Case 11), a sample with 
no information about the time between blood collection and protection from light/storage in a 
freezer (Case 6), and a sample from a patient whose mother had taken vitamin B6 
supplements until delivery (Case 7). 
 
Compared with the control ranges [9], the serum samples from all patients without ERT 
showed abnormally high PLP concentrations. PL concentrations were elevated in most of the 
samples but there was a sample with a reduced PL concentration from a patient with perinatal 
severe HPP with VB6-responsive seizures (Case 1). PA concentrations were mostly within 
normal limits but there were four older patients who had elevated PA. PLP-to-PL ratios were 
elevated in all patients. 
 
Scatter plots of serum PLP, PL, and PA concentrations, the PLP-to-PL ratio, and the urine 
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PEA concentration against serum ALP activity are presented in Supplementary Figure 1. After 
excluding the three serum samples that were inappropriate for statistical analysis, correlation 
analysis revealed that the PLP concentration (ρ = −0.554, p = 0.0349) and the PLP-to-PL ratio 
(ρ = −0.721, p = 0.0033) correlated negatively with the ALP activity, but that the PL (ρ = 
0.291, p = 0.292), PA (ρ = 0.182, p = 0.516), and PEA (ρ = −0.268, p = 0.315) concentrations 
did not correlate with ALP activity. 
 
Serum ALP activity, serum PLP, PL, and PA concentrations, the PLP-to-PL ratio, and the 
urine PEA concentration are plotted against clinical phenotype in Supplementary Figure 2. 
Serum ALP activities were lower in more severe phenotypes (perinatal severe and infantile 
HPP). Serum PLP concentrations and PLP-to-PL ratios were higher in more severe 
phenotypes. Serum PL concentrations were low in perinatal severe HPP. However, other 
phenotypes showed higher but relatively constant PL concentrations. Serum PA 
concentrations did not show a clear difference among phenotypes. Urine PEA concentrations 
were higher in more severe phenotypes. 
 
Because serum PLP, PL, and PA concentrations, and the PLP-to-PL ratio are age-related [9], 
we investigated the effect of age and phenotype severity (severe [perinatal severe HPP and 
infantile HPP] vs. mild [other phenotypes], analyzed as a categorical variable) on these values 
using multiple regression analysis. The PLP concentration was associated with phenotype 
severity (p < 0.0001) but not with age (p = 0.388). The PLP-to-PL ratio was also associated 
with phenotype severity (p = 0.0133) but not with age (p = 0.734). The PL concentration was 
associated with age (p = 0.0442) but not with the phenotype severity (p = 0.213). PA 
concentration was not associated with the phenotype severity (p = 0.381) or age (p = 0.500). 
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3.4. PLP, PL, and PA concentrations during ERT 
The results in samples with ERT are shown by open symbols in Figure 2. There were three 
serum samples with ERT stored immediately at 4°C but frozen 1–5 hours after blood 
collection (Cases 2, 8, and 17). With ERT, PLP concentrations showed normal or mildly 
elevated values. All cases in which pretreatment serum samples were also obtained had a 
remarkable reduction in the PLP concentration by ERT. PL concentrations were mildly 
elevated or within the normal limits. A patient with perinatal severe HPP with a remarkably 
low PL concentration (Case 1) showed normalization of PL concentration. Serum PA 
concentrations were mildly low or within normal limits. The PLP-to-PL ratios were reduced 
or low-normal in all patients. When PLP concentrations are plotted against PL concentrations, 
samples with and without ERT were separated well by the dashed line (y = 4x). This indicates 
that a PLP-to-PL ratio of approximately 4.0 is a good cut-off value to evaluate the effect of 
ERT. 
 
Two patients deserve additional attention. Case 7 had a rapid normalization of PLP and PL 
concentrations and a rapid reduction of the PLP-to-PL ratio in only 5 days (two injections of 
asfotase alfa). Case 17 had temporary discontinuation of ERT. This caused elevation of the 
PLP concentration and the PLP-to-PL ratio, which were reduced again by restarting ERT. 
 
3.5. PLP, PL, and PA concentrations plotted against serum ALP activity in all samples 
The assay results in all serum samples with and without ERT are plotted together in Figure 3. 
Correlation analysis revealed that the serum PLP concentration (ρ = −0.855, p < 0.0001) and 
PLP-to-PL ratio (ρ = −0.914, p < 0.0001) had strong negative correlations with serum ALP 
activity. Serum PL concentration showed a moderate positive correlation with ALP activity (ρ 
= 0.558, p = 0.0046) but serum PA (ρ = −0.136, p = 0.526) and urine PEA (ρ = −0.407, p = 
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0.0834) did not show a correlation with ALP activity. 
 
4. Discussion 
We conducted the assay for serum PLP, PL, and PA concentrations in HPP patients with and 
without ERT to confirm the usefulness of these metabolites as a diagnostic marker of HPP and 
to show the potential use of this assay to monitor the effect of ERT. We confirmed that an 
elevated serum PLP-to-PL ratio is a good diagnostic marker for HPP, along with other 
markers such as low serum ALP activity, elevated serum PLP concentration, and elevated 
urine PEA concentration [12]. We also demonstrated that the serum PLP-to-PL ratio reflected 
the effect of ERT more clearly than serum PLP and urine PEA concentrations. The PLP-to-PL 
ratio may be useful to evaluate the early effect of ERT before actual improvement in skeletal 
symptoms occurs. Because ERT is expensive, the PLP-to-PL ratio could be used to optimize 
asfotase alfa dosing and to monitor compliance in the subcutaneously administered ERT. We 
demonstrated that a PLP-to-PL ratio of approximately 4.0 is a good cut-off value to evaluate 
the effect of ERT. This cut-off value corresponds well to the upper limit of the serum 
PLP-to-PL ratio that was shown in previous studies [9, 13]. 
 
Elevated PL concentrations in most cases could be explained by highly excessive amount of 
PLP and residual TNSALP activity, which allows production of PL. Two patients with 
perinatal severe HPP and VB6-responsive seizures had the lowest PL concentrations among 
those at 0–1 months of age. PLP is essential to synthesize gamma-aminobutyric acid, a major 
inhibitory neurotransmitter in the brain. Because PLP cannot cross the blood-brain barrier, 
PLP must be dephosphorylated to PL by membrane-bound TNSALP to reach the brain [3]. 
Low serum PL concentrations suggest an insufficient supply of PLP to the brain and this may 
be a good indicator to consider ERT to prevent epileptic seizures, especially in neonatal 
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patients. Changes in the PL concentration with ERT were not as remarkable as those of the 
PLP concentration, particularly with older patients. Because PL is membrane-permeable, extra 
PL produced by a high ALP activity probably diffuses rapidly to the body tissues, keeping the 
serum PL concentration relatively constant. 
 
Many commercial laboratories measure PLP alone as a VB6 assay. Our findings indicate the 
importance of measuring both PLP and PL. Having laboratories specifically report PLP and 
PL concentrations, if possible, will be helpful for clinicians to calculate the PLP-to-PL ratio 
and estimate the risk of VB6-responsive seizures based on the PL concentration. 
 
When investigating the effect of ERT on serum PLP and PL concentrations, we checked the 
reliability of the PLP and PL assay for serum samples with asfotase alfa. Because 
derivatization of serum samples by semicarbazide takes 30 minutes, we first confirmed that 
the derivatization procedure did not significantly alter the PLP and PL concentrations by 
comparing between serum samples with and without levamisole. We then demonstrated that 
keeping the samples at 24°C for 1 hour without levamisole changed PLP and PL 
concentrations to a mild degree (<10%). The changes were less evident with the samples kept 
at 4°C for 1 hour. Therefore, when using regular serum collection tubes, we suggest that the 
blood samples should be protected from light to prevent photodegradation of PLP and cooled 
after collection, and that serum should be separated using a refrigerated centrifuge and frozen 
as soon as possible to obtain precise results. However, even though this is not possible in a 
clinical setting, if a blood sample is protected from light immediately after collection and 
serum is separated at room temperature and frozen within 1 hour, changes in PLP and PL 
concentrations will not be great enough to cause clinical misjudgment. 
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This study is limited by the small sample size. The sample collection procedure was not 
strictly controlled, although we recommended to separate and freeze serum within 1 hour after 
blood collection. Future directions include elucidating how concentrations of PLP and other 
related metabolites are associated with neurological and developmental symptoms, and how 
the assay of these metabolites can be used to determine the optimal dosing of asfotase alfa. 
 
5. Conclusions 
We confirmed the usefulness of the serum PLP-to-PL ratio and PLP concentration as a 
diagnostic marker of HPP. These measures are associated with serum ALP activity and 
clinical phenotypes. The PL concentration was low only in perinatal severe HPP. ERT with 
asfotase alfa decreased the PLP-to-PL ratio to mildly reduced or a low-normal level, and 
decreased the PLP concentration to normal or a mildly elevated level. ERT also normalized 
the low PL concentration in perinatal severe HPP. The PLP-to-PL ratio is a better indicator of 
the effect of, and patient compliance with, ERT than serum PLP and urine PEA concentrations, 
and a PLP-to-PL ratio of <4.0 is a good indicator of the effect of, and patient compliance with, 
ERT. The assay of these metabolites is considered to be helpful in the assessment of in vivo 
ALP activity in the blood during ERT. 
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Figure 1 
Stability of PLP and PL in different pre-treatment conditions 
PLP and PL concentrations were measured after four pre-treatment conditions: addition of 
levamisole; no levamisole; no levamisole and storage for 60 min at 4°C; and no levamisole 
and storage for 60 min at 24°C. Although pre-treatment with no levamisole and storage for 60 
min at 24°C showed the greatest changes in PLP and PL concentrations, the degree of the 
changes were within ±10%. PLP, pyridoxal 5′-phosphate; PL, pyridoxal 
 
Figure 2 
Concentrations of PLP, PL, and PA, and the PLP-to-PL ratio (PLP/PL) in all serum samples 
PLP, PL, and PA concentrations and the PLP-to-PL ratio are plotted against age (top two 
rows). Closed and open symbols represent serum samples without and with enzyme 
replacement therapy, respectively. Samples from the same patients are connected by lines in 
the same symbol shape. Samples that were inappropriate for statistical analysis are indicated 
by oblique lines over the symbols. Dashed lines represent reference ranges [9]. The scatter 
plot of PL vs. PLP (bottom row) demonstrates that serum samples with and without asfotase 
alfa are separated well by the dashed line (y = 4x). This indicates that a PLP-to-PL ratio of 
approximately 4.0 is a good cut-off value to evaluate the effect of asfotase alfa. 
PLP, pyridoxal 5′-phosphate; PL, pyridoxal; PA, 4-pyridoxic acid 
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Figure 3 
Serum ALP activity compared with serum PLP, PL, and PA concentrations, the PLP-to-PL 
ratio (PLP/PL), and the urine PEA concentration with and without ERT 
Circles indicate samples without ERT and squares indicate samples with ERT. Open symbols 
indicate samples that were inappropriate for statistical analysis. Serum PLP concentration and 
the PLP-to-PL ratio correlated negatively with serum ALP activity. The serum PL 
concentration correlated positively with serum ALP activity. The serum PA concentration and 
the urine PEA concentration did not correlate with serum ALP activity. 
ALP, alkaline phosphatase; PLP, pyridoxal 5′-phosphate; PL, pyridoxal; PA, 4-pyridoxic acid; 
PEA, phosphoethanolamine; ERT, enzyme replacement therapy 
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Supplementary Figure 1 
Serum ALP activity vs. serum concentrations of PLP, PL, and PA, the PLP-to-PL ratio 
(PLP/PL), and the urine PEA concentration without enzyme replacement therapy 
The shape of symbols represents the clinical phenotype. Open symbols indicate samples that 
were inappropriate for statistical analysis. Serum PLP concentration and the PLP-to-PL ratio 
correlated negatively with ALP activity. Serum PL and PA concentrations and the urine PEA 
concentration did not correlate with ALP activity. 
ALP, alkaline phosphatase; PLP, pyridoxal 5′-phosphate; PL, pyridoxal; PA, 4-pyridoxic acid; 
PEA, phosphoethanolamine 
 
Supplementary Figure 2 
Clinical phenotype vs. serum ALP activity, serum PLP, PL, and PA concentrations, the 
PLP-to-PL ratio (PLP/PL), and the urine PEA concentration 
In each clinical phenotype, the same symbol shape in the six graphs represents the same 
individual patient. Open symbols indicate serum samples with inappropriate storage 
conditions for PLP, PL, and PA assays. Serum ALP activities showed lower values in more 
severe phenotypes (perinatal severe and infantile hypophosphatasia). Serum PLP 
concentrations and PLP-to-PL ratios were higher in more severe phenotypes. Serum PL 
concentrations were low in perinatal severe HPP but other phenotypes showed higher and 
relatively constant values. Serum PA concentrations did not show a difference among 
phenotypes. Urine PEA concentrations were higher in more severe phenotypes. 
ALP, alkaline phosphatase; PLP, pyridoxal 5′-phosphate; PL, pyridoxal; PA, 4-pyridoxic acid; 
PEA, phosphoethanolamine 
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Table 1 
Clinical characteristics of subjects 
No. Sex Asfotase alfa 
(/week) 
Epileptic 
seizures 
mRS 
(last six 
months) 
Age Serum ALP 
(U/L) 
Serum PLP 
(nmol/L) 
Serum PL 
(nmol/L) 
Serum PA 
(nmol/L) 
Urine PEA 
(µmol/mol 
creatinine) 
ALPL gene analysis 
(NM_000478.5, 
NP_000469.3) 
Perinatal severe hypophosphatasia 
1 F  + (VB6 
responsive) 
5 0y 0m 1d 14 
(reference: 
530–1610) 
2414 
(21–188) 
7 
(18–106) 
5 
(4–38) 
1321 
(0–53) 
c.1559delT, p.L520fs; 
c.1023T>G, p.H341Q 
  2 mg/kg×3  5 0y 1m 11399 
(510–1620) 
92 
(21–188) 
85 
(18–106) 
15 
(4–38) 
  
2 M 2 mg/kg×3  4 0y 7m 41600 
(410–1560) 
40 
(21–188) 
56 
(18–106) 
4 
(4–38) 
 c.1559delT, p.L520fs; 
c.1436A>G, p.Y479C 
  1.8 mg/kg×3  4 1y 3m 12409 
(395–1339) 
93 
(16–57) 
55 
(9–28) 
2 
(6–26) 
  
  1.5 mg/kg×3  4 1y 10m 17321 
(395–1339) 
66* 
(16–57) 
57* 
(9–28) 
5* 
(6–26) 
142 
(0–23) 
 
3 F 2 mg/kg×3  4 1y 9m 37700 
(395–1289) 
51 
(16–57) 
67 
(9–28) 
11 
(6–26) 
1 
(0–23) 
c.1559delT, p.L520fs 
(homozygous) 
  2 mg/kg×3  3 2y 7m 31335 
(410–1150) 
25 
(16–57) 
35 
(9–28) 
8 
(6–26) 
1 
(0–20) 
 
4 F  + (VB6 
responsive) 
5 0y 0m 0d 11 
(530–1610) 
3096 
(21–188) 
28 
(18–106) 
35 
(4–38) 
316 
(0–53) 
c.1559delT, p.L520fs; 
c.562T>C, p.S188P 
  2 mg/kg×3  1 1y 0m 41035 
 
40 
(16–57) 
49 
(9–28) 
40 
(6–26) 
185 
(0–42) 
 
Perinatal benign hypophosphatasia 
5 F   1 0y 0m 0d 132 
(530–1610) 
597 
(21–188) 
97 
(18–106) 
27 
(4–38) 
25 
(0–53) 
c.1559delT, p.L520fs; 
c979T>C, p.F327L 
6 M  + (VB6 
responsiveness 
unknown 
1 0y 1m 375 
(510–1620) 
1125† 
(21–188) 
216† 
(18–106) 
26† 
(4–38) 
125 
(0–42) 
c.186G>A, p.M62I 
(heterozygous) 
7 F   1 0y 0m 0d 83 
(530–1610) 
2235‡ 
(21–188) 
677‡ 
(18–106) 
39‡ 
(4–38) 
 
c.1559delT, p.L520fs; 
c979T>C, p.F327L 
  2 mg/kg×3  1 0y 0m 5d 15420 
(530–1610) 
33 
(21–188) 
67 
(18–106) 
8 
(4–38) 
  
8 F   1 11y 8m 237 
(400–1450) 
403 
(15–57) 
23 
(7–18) 
7 
(6–18) 
 c.1559delT, p.L520fs; 
c979T>C, p.F327L 
  1 mg/kg×3  0 12y 2m 5483 
(300–1380) 
60* 
(15–57) 
35* 
(7–18) 
10* 
(6–18) 
31 
(0–5) 
 
Infantile hypophosphatasia 
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9 F   1 0y 7m 50 
(410–1560) 
2973 
(21–188) 
54 
(18–106) 
6 
(4–38) 
273 
(0–33) 
c.319G>A, p.V107I; 
c.1403C>T, p.A468V 
10 F   2 12y 2m 29 
(300–1380) 
3101 
(15–57) 
45 
(7–18) 
13 
(6–18) 
94 
(0–5) 
c.319G>A, p.V107I; 
c.1403C>T, p.A468V 
11 M  + (VB6 
non-responsive) 
4 12y 11m 109 
(455–1500) 
475** 
(15–57) 
22** 
(7–18) 
14** 
(6–18) 
96 
(0–5) 
c.1483G>A, p.G495S 
(homozygous) 
  2 mg/kg×3  4 13y 2m 17719 
(400–1450) 
49 
(15–57) 
47 
(7–18) 
18 
(6–18) 
31 
(0–5) 
 
Childhood hypophosphatasia 
12 F   1 4y 10m 259 
(430–1150) 
223 
(16–57) 
50 
(9–28) 
138 
(6–26) 
50 
(0–14) 
c.1559delT, p.L520fs 
(heterozygous) 
13 F   2 10y 6m 102 
(470–1450) 
1815 
(15–57) 
44 
(7–18) 
10 
(6–18) 
328 
(0–6) 
c.1559delT, p.L520fs; 
c.678G>A, p.M226I 
14 M   1 6y 6m 439 
(440–1230) 
196 
(16–57) 
33 
(9–28) 
20 
(6–26) 
41 
(0–11) 
c.1559delT, p.L520fs 
(heterozygous) 
Adult hypophosphatasia 
15 F   1 47y 10m 85 
(120–340) 
141 
(15–57) 
16 
(7–18) 
18 
(6–18) 
15 
(0–3) 
c.1559delT, p.L520fs 
(heterozygous) 
16 F  + (VB6 
responsiveness 
unknown 
0 19y 2m 54 
(120–370) 
321 
(15–57) 
26 
(7–18) 
13 
(6–18) 
12 
(0–3) 
c.1559delT, p.L520fs 
(heterozygous) 
Odontohypophosphatasia 
17 M 1.5 mg/kg×2  1 11y 9m 10988 
(470–1500) 
63* 
(15–57) 
49* 
(7–18) 
10* 
(6–18) 
 Not tested 
    1 12y 11m 325 
(455–1500) 
596 
(15–57) 
40 
(7–18) 
8 
(6–18) 
42 
(0–5) 
 
  1 mg/kg×2  1 13y 2m 5158 
(400–1450) 
158 
(15–57) 
67 
(7–18) 
9 
(6–18) 
31 
(0–5) 
 
18 F   1 39y 4m 76 
(120–340) 
113 
(15–57) 
16 
(7–18) 
29 
(6–18) 
13 
(0–3) 
c.1559delT, p.L520fs 
(heterozygous) 
19 M   1 7y 3m 205 
(450–1250) 
379 
(15–57) 
32 
(7–18) 
14 
(6–18) 
35 
(0–10) 
c.550C>T, p.R184W 
(heterozygous) 
20 M   0 11y 10m 288 
(470–1500) 
291 
(15–57) 
46 
(7–18) 
28 
(6–18) 
19 
(0–6) 
c.1015G>A, p.G339R 
(heterozygous) 
mRS, modified Rankin scale; ALP, alkaline phosphatase; PLP, pyridoxal 5′-phosphate; PL, pyridoxal; PEA, phosphoethanolamine;  
VB6, vitamin B6, d, days; m, months; y, years 
† Time between blood collection and protection from light/storage in a freezer was not documented. 
‡ Mother took vitamin B6 supplements until delivery. 
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* Samples were stored at 4°C immediately but frozen 1–5 hours after blood collection. 
** Sample was protected from light 1–5 hours after blood collection. 
Reference values: serum ALP from Tanaka et al. [14]; serum PLP, PL, and PA from Akiyama et al. [9]; urine PEA from Imbard et al. [15]. For 
serum ALP, reference values for 20 years old are shown for patients over 20 years old. For serum PLP, PL, and PA, reference values for 4–11 
months old are shown for patients under 4 months old, and those for 7–17 years old are shown for patients over 17 years old. For urine PEA, 
reference values for 18–19 years old are shown for patients over 19 years old. 
 
